Option chain shows key data for Relief Therapeutics's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Relief Therapeutics.

Relief Therapeutics (OTC:RLFTF) Stock, Option Chain

Relief Therapeutics Holding SA is engaged in the research, development, and commercialization of biopharmaceutical products. It mainly develops drugs of natural human origin. It has a focus on commercial products, and the development program pipeline is focused on three main areas: rare genetic, metabolic disorders, rare connective tissue disorders, and rare lung diseases. Its pipeline includes various drug candidates in their different stages of development, such as RLF-TD011 and RLF-100, among others. It also has commercial legacy products like Cambia, Setofilm, Voltadol, and Voltfast, among others. Geographically, the company generates a majority of its revenue from Europe (excluding Switzerland) and the rest from North America, Switzerland, and the rest of the world.

Biotech

News

Penny Stocks

Health Care

Legal

General

NRXP

RLFTD

RLFTF

Relief Therapeutics, NRx Pharma Settle Litigation Regarding COVID-19 Treatment Candidate

Earnings

Large Cap

Financing

Small Cap

IPOs

ABBV

ACER

ALNY

ARGX

ATXS

CYCN

LXRX

NVCR

RARE

TNXP

Here&#39;s a roundup of top developments in the biotech space over the last 24 hours:

Daily Biotech Pulse: GSK&#39;s Kidney Disease Drug Approved For Children, Tonix Pharma To Launch Monkeypox Vaccine Study In Kenya, Positive Effect Of Cyclerion&#39;s Schizophrenia Candidate

Trading Ideas

ARQT

BGNE

HZNP

INCY

REGN

RYTM

SPRO

The biotech sector is poised to end June on a positive note, despite largely disappointing regulatory decisions scheduled during the month, thanks to a reversal in broader market sentiment.

Attention Biotech Investors: Mark Your Calendar For These July PDUFA Dates

RELIEF THERAPEUTICS HLDG by RELIEF THERAPEUTICS HLDG AG

Relief Therapeutics Holding SA

Press Releases

Relief Therapeutics Announces Final Readout of PKU GOLIKE Clinical Trial

Relief Therapeutics Provides Update on Potential Transaction with Renexxion

Relief Therapeutics Completes Strategic Transition with Sale of GOLIKE Rights ex-US

Relief Therapeutics Announces European Patent Office Decision to Grant Patent for RLF-TD011

Relief Therapeutics Announces Conclusion of Merger Discussions with Renexxion

Relief Therapeutics Reports 2024 Financial Results and Provides Corporate Update

Relief Therapeutics Publishes 2025 Annual General Meeting Agenda

Relief Therapeutics Receives FDA Rare Pediatric Disease Designation for RLF-TD011

Relief Therapeutics Announces Results of Annual General Meeting

Relief Therapeutics Receives FDA Response to QIDP Request for RLF-TD011

RLFTY

Relief Therapeutics

Comments

Relief Therapeutics

Relief Therapeutics (RLFTF) Options

No option chain data available. Please try again later

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell